UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10

UT 西南 NCI 国家临床试验网络主要学术网站 - U10

• 批准号: 9248972
• 负责人: David Eric Gerber
• 金额: $ 70万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-09 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9248972
• 关键词: Academic Medical Centers; Adult; African American; American Cancer Society; American College of Radiology Imaging Network; American College of Surgeons Oncology Group; American Society of Clinical Oncology; Area; Basic Science; Breast; Cancer Center; Chest; Clinic; Clinical; Clinical Research; Clinical Trials; Collaborations; Country; Department chair; Discipline; Disease; Eastern Cooperative Oncology Group; Enrollment; Ethics; Ethnic Origin; Faculty; Funding; Grant; Gynecologic Oncology Group; Head and neck structure; Hematology; Heme; Hispanics; Image; Institution; Lead; Leadership; Lung; Magnetic Resonance Imaging; Malignant neoplasm of lung; Medical center; Mentors; NCI-Designated Cancer Center; National Clinical Trials Network; National Surgical Adjuvant Breast and Bowel Project; Oncology Group; Patients; Physician Executives; Population; Positioning Attribute; Positron-Emission Tomography; Principal Investigator; Publications; Radiation Oncology; Radiation Therapy Oncology Group; Recording of previous events; Recruitment Activity; Research; Research Personnel; Role; Services; Site; Southwest Oncology Group; Texas; Therapeutic; Translating; Translational Research; Universities; cancer diagnosis; career development; drug discovery; ethnic diversity; ethnic minority population; innovation; medical schools; member; metropolitan; multidisciplinary; neuro-oncology; oncology; patient oriented; patient population; programs; public health relevance; quantitative imaging; racial and ethnic; racial minority; translational scientist

DESCRIPTION (provided by applicant): The University of Texas Southwestern Medical Center (UTSW) has a history of leadership, translational research, and accrual to cooperative group trials. The PI of this grant is Dr. Joan Schiller, chief of the Division of Heme/Oncology and Deputy Director of the Simmons Cancer Center (SCC), former Chair of ECOG's Thoracic Committee and currently PI of UTSW's main institution ECOG grant. Co-investigators include Dr. Hak Choy, Chair of UTSW's Department of Radiation Oncology, Vice Chair for Disease Sites in RTOG, and former Chair of RTOG's Thoracic Committee; Dr. David Miller, member of the GOG Board of Directors and Chair of the Uterine Corpus Committee; Dr. Marilyn Leitch, member of the Executive Committee of ACOSOG, and Dr. Phil Evans, immediate past president of the American Cancer Society, who was one of the founding members of the ACRIN Breast committee, and served as the principal investigator at UTSW for ACRIN sponsored trials. In 2012, UTSW enrolled 105 patients on adult co-operative group trials. Since 2006, UTSW faculty have investigated or co-investigated 96 co-operative group publications and 85 abstracts, and have chaired, co-chaired, or served as cooperative committee chair on 34 cooperative group trials. UTSW is also a site for the NCI Centers Quantitative imaging Excellence. UTSW is the only academic medical center and medical school in the Dallas/Ft. Worth (DFW) Metroplex, the fourth largest metropolitan area in the country, and is the only NCI designated Cancer Center in north Texas. UTSW also has a strong clinical and transitional research program and drug discovery program; a SPORE in lung cancer; an Advanced Imaging Research Center; and has access to a diverse ethnic and racial population. In the DFW Metroplex, roughly 10.3% of the populations with a cancer diagnosis are Hispanic, and 14.1% are African American; in 2012, 29.6% of SCC patients going on co-operative group clinical studies were of Hispanic ethnicity, and 13.6% were of African American ancestry. The specific aims of the UTSW UIO are to contribute to and promote: (1) The NCTN by enrolling patients with diverse ethnic and racial background on therapeutic and non-therapeutic trials; (2) The scientific direction of the NCTN by bringing the basic, translational, and imaging research conducted at UTSW into hypothesis driven clinical trials. (3) Multidisciplinary efforts and collaboration across multiple disciplinesand multiple cooperative groups; (4) Service in leadership roles by chairing and co-chairing clinical trials and committees, and by participating in NCI activities and initiatives; and (5) The career development of junior faculty.

描述（由申请人提供）：得克萨斯大学西南医学中心（UTSW）具有领导，转化研究和合作组试验的历史。该基金的PI是Joan Schiller博士，血红素/肿瘤科主任， 西蒙斯癌症中心（SCC）副主任，前ECOG胸科委员会主席，现任UTSW主要机构ECOG补助金的PI。合作研究者包括UTSW放射肿瘤学系主任、RTOG疾病部位副主席和RTOG胸部委员会前主席Hak Choy博士; GOG董事会成员和子宫体委员会主席大卫米勒博士; ACOSOG执行委员会成员Marilyn Leitch博士和美国癌症协会前任主席Phil Evans博士，她是ACRIN乳腺委员会的创始成员之一，并担任UTSW ACRIN赞助试验的首席研究员。2012年，UTSW招募了105名成人合作组试验患者。自2006年以来，UTSW教师已经调查或合作调查了96合作组出版物和85摘要，并主持，共同主持，或担任34合作组试验的合作委员会主席。UTSW也是NCI定量成像卓越中心的所在地。 UTSW是达拉斯/英尺唯一的学术医疗中心和医学院。沃思（DFW）大都会区，全国第四大都市区，是唯一的NCI指定癌症中心在北德克萨斯州。UTSW还拥有强大的临床和过渡研究计划和药物发现计划;肺癌的SPORE;先进的成像研究中心;并有机会接触到不同的民族和种族人口。在DFW Metroplex中，大约10.3%的癌症诊断人群是西班牙裔，14.1%是非洲裔美国人; 2012年，29.6%的SCC患者参加了合作组临床研究，西班牙裔种族，13.6%是非洲裔美国人。 UTSW UIO的具体目标是促进和促进：（1）NCTN通过招募具有不同种族和种族背景的患者进行治疗和非治疗试验;（2）NCTN的科学方向，将UTSW进行的基础，转化和成像研究纳入假设驱动的临床试验。(3)多学科的努力和跨多学科和多个合作小组的合作;（4）通过主持和共同主持临床试验和委员会，并通过参与NCI活动和倡议的领导角色服务;和（5）初级教师的职业发展。